Antiparasitic Wins FDA Approval for High-Risk Neuroblastoma Antiparasitic Wins FDA Approval for High-Risk Neuroblastoma

The FDA approved eflornithine to treat this rare cancer in adult and pediatric patients. The drug has also been approved to reduce excessive facial hair growth and to treat sleeping sickness.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology Source Type: news